🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome

RecruitingNAAges 18 Years - anyAllNew Valley University
NCT07743242 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and/or obstetric morbidity with persistent antiphospholipid antibodies (aPL).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged ≥18 years * Patients with anemia consistant with hemolysis. * Patient diagnosed with antiphospholipid syndrome. * Informed consent obtained Exclusion Criteria: * Age less than 18 years. * Other causes of anemia than autoimmune hemolysis.
💊

What it tests

  • Hemoglobin
  • Coombs test
📍

Where

1 site
New Valley University
Al Khārjah, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy